Clinical trials: Relapse Management
Lymphocytic Leukemia, Chronic
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia
This multi-center, prospective, observational study will describe the management of relapsing or refractory chronic lymphocytic leukemia (CLL) patients. Data will be collected for 2 years.
- Trial name
- NCT01488162
- Where
- 84 sites in France
- Volunteers
- 327 people
- Sponsor
- Hoffmann-La Roche
Relapsing Remitting Multiple Sclerosis
Administration of Fingolimod in Greek Patients With Multiple Sclerosis.
The goal of this observational study is to evaluate the efficacy of fingolimod through the estimation of the annualized relapse rate (ARR) over a period of 2 years.
- Trial name
- FILYRA (NCT06949956)
- Volunteers
- 140 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
CLL/SLL, Waldenstrom Macroglobulinemia
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies.
- Conditions
- CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- NCT04775745
- Testing
- LP-168
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Newave Pharmaceutical Inc
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
- Trial name
- NCT07134088
- Testing
- Blinatumomab
- Where
- 5 sites in United States, Japan
- Volunteers
- 104 people
- Sponsor
- Amgen
AML, MDS
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
This open-label Phase I study aims at assessing primarily the safety of the NKR-2 treatment administered after a non-myeloablative preconditioning regimen in r/r AML/MDS patients.
- Trial name
- DEPLETHINK (NCT03466320)
- Testing
- NKR-2
- Where
- 7 sites in United States, Belgium
- Volunteers
- 21 people
- Sponsor
- Celyad Oncology SA
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
The purpose of the study is to assess the efficacy, safety, and tolerability of two doses of laquinimod compared to Avonex®
- Trial name
- LIBRETTO (NCT01975298)
- Testing
- Laquinimod, Avonex®
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of…
- Trial name
- CONCERTO (NCT01707992)
- Testing
- Laquinimod
- Where
- 284 sites in United States, Austria and 28 more
- Volunteers
- 2,199 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Non-Hodgkin's Lymphoma
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
Primary Objective: To evaluate the safety and tolerability of subcutaneous (SC) blinatumomab dose administrations Secondary Objectives: To determine pharmacokinetics (PK) with continuous intravenous (cIV) and SC administrations…
- Trial name
- NCT02961881
- Testing
- blinatumomab
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 35 people
- Sponsor
- Amgen
Non Hodgkin Lymphoma, Richter Transformation
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing…
- Conditions
- Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia
- Trial name
- NCT04771572
- Testing
- LP-118
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Newave Pharmaceutical Inc
B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
The primary objective of this study is to evaluate the efficacy of blinatumomab.
- Trial name
- NCT06054113
- Testing
- Blinatumomab
- Where
- 7 sites in China
- Volunteers
- 18 people
- Sponsor
- Amgen
Osteosarcoma, Sarcoma
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT05830123
- Testing
- HS-20093
- Where
- 11 sites in China
- Volunteers
- 170 people
- Sponsor
- Hansoh BioMedical R&D Company
Relapsing Remitting Multiple Sclerosis
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
The main purpose of this study is to assess the usability and value of the multiple sclerosis (MS) care management platform in terms of improved monitoring of people with MS (pwMS) in clinical practice.
- Trial name
- ILLUMINATE (NCT05949580)
- Testing
- MS Care Platform (icobrain ms and icompanion ms)
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 500 people
- Sponsor
- Hoffmann-La Roche
Non-Hodgkin Lymphoma
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)
The purpose of this study is to determine whether interleukin-2 given 3 times weekly for 8 weeks in combination with rituximab is effective and safe when compared to rituximab given alone in the treatment of follicular NHL…
- Trial name
- NCT00100737
- Testing
- interleukin-2, rituximab
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Chiron Corporation
Relapsed/Refractory Non-Hodgkin's Lymphoma
A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
A pharmacokinetic study to access how the body absorbs and removes ABT-199 in adults with Non-Hodgkin's Lymphoma.
- Trial name
- NCT02095574
- Testing
- [14C]ABT-199 (GDC-0199)
- Sponsor
- AbbVie
Aplastic Anemia
A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia
This is a phase II, open label, multi-center, intra-patient dose escalation study to characterize the pharmacokinetics (PK) after oral administration of eltrombopag in combination with immunosuppressive therapy in pediatric…
- Trial name
- NCT03025698
- Testing
- Eltrombopag, hATG, CsA
- Where
- 20 sites in United States, Hong Kong and 4 more
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)
Aim of the BETAPATH study is to evaluate whether the use of a personal digital assistant (PDA) can improve the adherence of Multiple Sclerosis patients to a therapy with Betaseron.
- Trial name
- NCT00902135
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- Germany
- Volunteers
- 702 people
- Sponsor
- Bayer
Multiple Sclerosis
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
Determination the efficacy of daily oral treatment with laquinimod 0.6 mg capsules as compared to placebo in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- ALLEGRO (NCT00509145)
- Testing
- Laquinimod
- Where
- 144 sites in United States, Austria and 22 more
- Volunteers
- 1,106 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Myeloma
An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma
Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamics
- Trial name
- NCT02182141
- Testing
- BIBF 1120 ES
- Volunteers
- 17 people
- Sponsor
- Boehringer Ingelheim
Patients With Advanced Solid Tumors
Safety and Tolerability of Intravenous Administration of ICVB-1042
Study to evaluate the safety and tolerability of intravenous ICVB-1042
- Trial name
- ICVB-1042 (NCT05904236)
- Testing
- Treatment with ICVB-1042 administered intravenously
- Where
- 10 sites in United States
- Volunteers
- 17 people
- Sponsor
- IconOVir Bio
Relapsing-remitting Multiple Sclerosis
Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA
Primary Objective: To assess the distribution of IARs by severity grade when LEMTRADA is administered to RRMS patients who will be medicated according to specified algorithm designed to manage infusion associated reactions.
- Trial name
- EMERALD (NCT02205489)
- Testing
- Alemtuzumab GZ402673, cetirizine, ranitidine
- Where
- 20 sites in Belgium, France and 2 more
- Volunteers
- 58 people
- Sponsor
- Genzyme, a Sanofi Company